One of the stocks to have emerged as one of the notable gainers on Wednesday was that of Pressure BioSciences Inc (OTCMKTS:PBIO) and it is quite likely that the stock is going to come into focus among investors today.

Market Action

On Wednesday, PBIO stock fell 0.90% to $1.10 with 37K shares, compared to its average volume of  12K shares. The stock moved within a range of $0.9116 – 1.2750 after opening trade at $1.15.

Following a key announcement yesterday from the company with regards to its partnership with DrDeneseSkinScience, the Pressure BioSciences stock went on a strong rally and ended up with gains of as much as 14.41% for the day. In light of the gains, it may be a good idea to take a closer look at the actual news. The company announced yesterday the confirmation of its rollout plans for some of the specific products from DrDeneseSkinScience.

The company had actually provided the details of the rollouts at the Development of a New Generation of Skincare Products webinar that had been sponsored by the FORCE Family Office. It could well be a major new partnership for the company considering the fact that Dr. Denese is regarded as one of the best-known innovators in the world of scientific skincare.

In the announcement that was made yesterday, it was noted that the collaboration between the two companies is going to be focussed on three specific areas. One of those is hair loss prevention and hair growth, the second is retinol and the third one is lipid-soluble Vitamin C.

In light of the latest announcement of the specific products that are going to be rolled out, there was significant optimism among investors with regard to the Pressure BioSciences stock. The Senior Scientist at Pressure BioSciences Gary Smejkal spoke about the progress made by the company as well. He noted that it had made significant progress with regard to the retinol and soluble Vitamin C-related products as well.

Traders Note

PBIO stock is trading below the 20-Day and 50-Day Moving averages of $1.27 and $1.44 respectively. Moreover, the stock is trading below the 200-Day moving average of $1.75.

By Nitin Harlalka

I am Nitin Harlalka, and I have been a passionate writer for close to a decade. I have a graduate degree in Economics and have worked as a business writer for a range of publications. Over the past couple of years, I have also started working on emerging industries like the cannabis industry and blockchain.

Leave a Reply

Your email address will not be published.